Canada clears Cyberonic's VNS (vagus nerve stimulation) therapy for depression:
This article was originally published in Clinica
Executive Summary
Cyberonics has gained the go-ahead in Canada to market its implantable vagus nerve stimulation (VNS) device for the treatment of chronic or recurrent depression. The NeuroCybernetic Prosthesis system, which is indicated for use in patients who are resistant or intolerant, can now be targeted at around 100,000 Canadians who suffer form the condition, says the Houston, Texas company. The product first became available as a treatment for depression in Europe last month (see Clinica No 950, p 17).
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.